Zuo Weilun, Li Jingyan, Jiang Wenwen, Zhang Mengyao, Ma Yan, Gu Qin, Wang Xiaoyu, Cai Lukui, Shi Li, Sun Mingbo
Yunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Diseases, Institute of Medical Biology, Chinese Academy of Medical Sciences, Peking Union Medical College, Kunming, China.
Laboratory of Vaccine Development, Institute of Medical Biology, Chinese Academy of Medical Sciences, Peking Union Medical College, Kunming, China.
Front Microbiol. 2021 Oct 25;12:757375. doi: 10.3389/fmicb.2021.757375. eCollection 2021.
Dose-sparing intradermal (ID) vaccination may induce the same immune responses as intramuscular (IM) vaccination, which can increase vaccine supplies and save costs. In this study, rats were immunized with fractional-dose of Sabin-derived IPV combined with diphtheria-tetanus-acellular pertussis vaccine (DTaP-sIPV) intradermally with hollow microneedle devices called MicronJet600 and the vaccine immunogenicity and efficacy were evaluated and compared with those of full-dose intramuscular immunization. We tested levels of antibodies and the subclass distribution achieved different immunization routes. Furthermore, gene transcription in the lung and spleen, cytokine levels and protection against infection were also examined. The humoral immune effect of DTaP-sIPV delivered with MicronJet600 revealed that this approach had a significant dose-sparing effect and induced more effective protection against infection by causing Th1/Th17 responses. In conclusion, ID immunization of DTaP-sIPV with the MicronJet600 is a better choice than IM immunization, and it has the potential to be a new DTaP-sIPV vaccination strategy.
剂量节省型皮内(ID)接种疫苗可能诱导与肌肉内(IM)接种疫苗相同的免疫反应,这可以增加疫苗供应并节省成本。在本研究中,用一种名为MicronJet600的中空微针装置对大鼠进行皮内接种分剂量的萨宾株脊髓灰质炎灭活疫苗(sIPV)联合白喉-破伤风-无细胞百日咳疫苗(DTaP-sIPV),并评估疫苗的免疫原性和效力,并与全剂量肌肉内免疫进行比较。我们检测了不同免疫途径所产生的抗体水平和亚类分布。此外,还检测了肺和脾中的基因转录、细胞因子水平以及对感染的保护作用。用MicronJet600接种DTaP-sIPV的体液免疫效果表明,这种方法具有显著的剂量节省效应,并通过引发Th1/Th17反应诱导了更有效的抗感染保护。总之,用MicronJet600进行DTaP-sIPV的皮内免疫是比肌肉内免疫更好的选择,并且它有可能成为一种新的DTaP-sIPV疫苗接种策略。